Summary
Adjuvant chemotherapy (CT) became the standard of care for patients with completely resected non-small cell lung cancer. However, the evidence supports this intervention for stages II-IIIA only. For stage IB, the randomized trials were not able co configure a clear-cut conclusion. Positive results have been published by the Japanese investigators using uracil-tegafur, whereas no survival benefit was observed in the trials using platinum-based CT. The new TNM staging system adopted in 2009 operated some modifications which partially included the former stage IB. Despite the fact that the new staging system is currently in use, the recommendations regarding adjuvant CT, as they appear in the guidelines, are based on the evidence built on the previous TNM classification. Subsequently, the issue regarding adjuvant CT in stage IB deserves a new perspective. This paper will address the new viewpoint regarding adjuvant CT in stage IB, defined according to the current evidence and the amendments of new TNM staging system.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Crino L, Weder W, van Meerbeeck J. et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice. Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21(Suppl 5): v103–v115, 2010
Pisters K, Evans W, Azzoli G, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I–IIIA Resectable Non-Small-Cell Lung Cancer Guideline. J Clin Oncol, 25: 5506–5518, 2007
Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst, 95: 1453–1461, 2003
Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med, 350: 351–360, 2004
Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial. Lancet Oncol, 7: 719–727, 2006
Butts C, Ding K, Seymour L, et al. Randomized Phase III Trial of Vinorelbine Plus Cisplatin Compared With Observation in Completely Resected Stage IB and II Non-Small-Cell Lung Cancer: Updated Survival Analysis of JBR-10. J Clin Oncol, 28: 29–34, 2010
Pignon J, Tribodet H, Scagliotti G, et al. Lung Adjuvant Cisplatin Evaluation: A Pooled Analysis by the LACE Collaborative Group. J Clin Oncol, 26: 3552–3559, 2008
Strauss G, Herndon J, Maddaus M, et al. Adjuvant Paclitaxel Plus Carboplatin Compared With Observation in Stage IB Non-Small-Cell Lung Cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol, 26: 5043–5051, 2008
Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol, 2: 706–714, 2007
Detterbeck F, Boffa D, Tanoue L, et al. The new lung cancer staging System. Chest, 136: 260–271, 2009
Ou I, Zell J, Ziogas A, et al. Prognostic significance of the non-size-based AJCC T2 descriptors: visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size. Chest, 133: 662–669, 2008
Padilla J, Calvo V, Penalver JC, et al. Surgical results and prognostic factors in early non-small cell lung cancer. Ann Thorac Surg, 63: 324–326, 1997
Martini N, Bains MS, Burt ME, et al. Incidence of local recurrence and second primary tumor in resected stage I lung cancer. J Thorac Cardiovasc Surg, 109: 120–129, 1995
Wu YC, Lin CF, Hsu WH, et al. Long-term results of pathological stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control. Eur J Cardiothorac Surg, 24: 994–1001, 2003
Han H, Silverman J, Santucci T, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol, 8: 72–79, 2005
Okada M, Nishio W, Sakamoto T, et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg, 129: 87–93, 2005
Moro-Sibilot D, Aubert A, Diab S, et al. Comorbidities and Charlson score in resected stage I nonsmall cell lung cancer. Eur Respir J, 26: 480–486, 2005
Horn L, Sandler A, Putnam J. The rationale for adjuvant chemotherapy in stage I non-small cell lung cancer. J Thorac Oncol, 2: 377–383, 2007
Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in nonsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355: 983–991, 2006
Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med, 355: 570–580, 2006
Chen HY, Yu SL, Chen Ch, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med, 356: 11–20, 2007
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dediu, M. Adjuvant chemotherapy in stage IB NSCLC: implication of the new TNM staging system. memo 4, 16–18 (2011). https://doi.org/10.1007/s12254-011-0239-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12254-011-0239-6